Allergy Therapeutics
AGY.L
#6967
Rank
A$0.72 B
Marketcap
$0.14
Share price
6.06%
Change (1 day)
212.53%
Change (1 year)

P/E ratio for Allergy Therapeutics (AGY.L)

P/E ratio at the end of 2023: -0.1179

According to Allergy Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -94.8313. At the end of 2023 the company had a P/E ratio of -0.1179.

P/E ratio history for Allergy Therapeutics from 2005 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2023-0.1179-98.86%
2022-10.3-120.28%
202151.0306.45%
202012.5-50.76%
201925.5-216.94%
2018-21.8-64.09%
2017-60.7681.62%
2016-7.76-100.86%
20158991173.85%
201470.69.3%
201364.6152.71%
201225.6-291.7%
2011-13.3-126.79%
201049.8-6712.28%
2009-0.75268.53%
2008-0.6935-74.49%
2007-2.72-63.49%
2006-7.45-60.13%
2005-18.7

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.